Keywords: Merck & Co, Endocyte, Vintafolide, Etarfolatide, Ovarian cancer, NSCLC, Companion diagnostic

Merck & Co in potential $1 billion deal for cancer drug candidate vintafolide

Article | 17 April 2012

Print This

US drug giant Merck & Co (NYSE: MRK) has entered into an agreement to develop and commercialize Endocyte's (Nasdaq: ECYT) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in